LABORATORY RESEARCH Interactions of Abiraterone, Eplerenone and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100 Abiraterone, a rationally-designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer, is often effective, but requires co-administration with glucocorticoids to curtail side effects. Here, researchers hypothesized that progressive disease on abiraterone may occur secondary to glucocorticoid-induced activation of mutated androgen receptor. [Cancer Res] Abstract Central Role for Proline-, Glutamic Acid-, and Leucine-Rich Cofactor Protein 1 in Nonandrogenic Activation of the Androgen Receptor in Prostate Cancer Here, researchers show the predominant estrogen receptor (ER) isoform expressed in prostate cancer specimens and cell lines is ERß. [Mol Endocrinol] Abstract Targeting Bone Remodeling by Isoflavone and 3,3′-Diindolylmethane in the Context of Prostate Cancer Bone Metastasis In this study, researchers found that prostate cancer cells could stimulate differentiation of osteoclasts and osteoblasts through the up-regulation of RANKL, RUNX2 and osteopontin, promoting bone remodeling. [PLoS One] Abstract Resveratrol Enhances Radiation Sensitivity in Prostate Cancer by Inhibiting Cell Proliferation and Promoting Cell Senescence and Apoptosis In this study, the effect of radiation therapy in combination with the radiosensitizing agent resveratrol was investigated in a radioresistant prostate cancer cell line, PC-3. [Cancer Sci] Abstract Therapeutic Targeting of Angiotensin II Receptor Type 1 to Regulate Androgen Receptor in Prostate Cancer Recent studies have demonstrated that an angiotensin II receptor blocker (ARB) has the potential to decrease serum prostate-specific antigen level and improve performance status in castration-resistant prostate cancer patients. These facts prompted researchers to investigate the direct effects of ARBs on prostate cancer growth and progression. [Prostate] Abstract Role of Dutasteride in Pre-Clinical ETS Fusion-Positive Prostate Cancer Models Here, researchers evaluated the expression levels of 5α-reductase isoenzymes in prostate cancer cell lines and tissues. They also tested the effect of dutasteride, a 5α-reductase inhibitor, in TMPRSS2–ERG fusion-positive VCaP cell proliferation and cell invasion. [Prostate] Abstract Peptides Binding to Prostate-Specific Antigen Enhance Its Antiangiogenic Activity Researchers hypothesized that factors stimulating the activity of prostate-specific antigen (PSA) could be used to reduce prostate tumor growth. Here, their aim was to study whether these peptides enhance the antiangiogenic activity of PSA. [Prostate] Abstract Novel Polypyridyl Chelators Deplete Cellular Zinc and Destabilize the X-Linked Inhibitor of Apoptosis Protein (XIAP) Prior to Induction of Apoptosis in Human Prostate and Breast Cancer Cells In this study, researchers show that treatment of PC-3 prostate cancer and MDA-MB-231 breast cancer cells with membrane-permeable zinc-chelators with different zinc affinities results in varying degrees of XIAP depletion. [J Cell Biochem] Abstract CLINICAL RESEARCH Prostate-Cancer Mortality at 11 Years of Follow-Up Researchers updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with two additional years of follow-up. [N Engl J Med] Abstract | Press Release Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients with Lymph Node Metastases Researchers evaluated the ability of positron emission tomography (PET)/computed tomography (CT) and magnetic resonance (MR) lymphography to assess the number, size, and location of lymph node metastases in patients with primary or recurrent prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract The Identification and Internal Validation of a Preoperative Serum Biomarker Panel to Determine Extracapsular Extension in Patients with Prostate Cancer Researchers followed a biomarker development pathway and compared the preoperative serum expressions of VEGF-D, PEDF, IGF-I, IGFBP3, and CD14 in patients from the Irish Prostate Cancer Research Consortium with radical prostatectomy determined extracapsular extension (ECE) against patients with nonECE. [Prostate] Abstract |